Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Oncology Letters|March 12, 2025
Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasisChen-Chuan Hsu, Li-Chung Chiu, How-Wen Ko, et al.
Oncology and Therapy|May 15, 2021
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination TherapyChin-Chou Wang, Li-Chung Chiu, Pi-Hung Tung, et al.
American Journal of Cancer Research|September 11, 2023
Clinical outcome analysis of non-small cell lung cancer patients with brain metastasis receiving metastatic brain tumor resection surgery: a multicenter observational studyPing-Chih Hsu, Li-Chung Chiu, Ko-Ting Chen, et al.
Therapeutic Advances in Medical Oncology|June 29, 2026
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysisPing-Chih Hsu, How-Wen Ko, Li-Chung Chiu, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational StudyPing-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, et al.
BMC Infectious Diseases|October 27, 2015
Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care unitsHan-Chung Hu, Kuo-Chin Kao, Li-Chung Chiu, et al.
Antibiotics (Basel, Switzerland)|November 27, 2024
Evaluating the Efficacy of Inhaled Colistin via Two Nebulizer Types in Ventilator-Associated Pneumonia: Prospective Randomized TrialChung-Chi Huang, Tien-Pei Fang, Chieh-Mo Lin, et al.
European Journal of Medical Research|January 28, 2025
Ventilatory variables and computed tomography features in COVID-19 ARDS and non-COVID-19-related ARDS: a prospective observational cohort studyLi-Chung Chiu, Hsin-Hsien Li, Yu-Hsiang Juan, et al.
Biomedical Journal|July 4, 2016
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesionsPing-Chih Hsu, Li-Chung Chiu, Shih-Hong Li, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Pageof 6